Nurix Therapeutics, Inc.
NRIX
$10.55
$0.313.03%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -30.25% | -29.15% | -17.76% | 2.25% | 94.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.25% | -29.15% | -17.76% | 2.25% | 94.02% |
| Cost of Revenue | 24.80% | 17.17% | 10.01% | 5.96% | 3.29% |
| Gross Profit | -64.40% | -48.97% | -26.31% | -7.78% | 22.71% |
| SG&A Expenses | 2.05% | 7.09% | 10.89% | 10.58% | 16.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.52% | 15.31% | 10.17% | 6.79% | 5.52% |
| Operating Income | -46.62% | -37.38% | -22.27% | -8.47% | 14.53% |
| Income Before Tax | -43.96% | -34.28% | -18.83% | -4.69% | 18.99% |
| Income Tax Expenses | 100.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.99% | -34.47% | -19.01% | -4.81% | 18.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.99% | -34.47% | -19.01% | -4.81% | 18.94% |
| EBIT | -46.62% | -37.38% | -22.27% | -8.47% | 14.53% |
| EBITDA | -47.34% | -37.65% | -22.31% | -7.92% | 15.77% |
| EPS Basic | -5.92% | -9.10% | -5.94% | 1.63% | 24.90% |
| Normalized Basic EPS | -5.88% | -8.93% | -5.78% | 1.73% | 24.94% |
| EPS Diluted | -5.92% | -9.10% | -5.94% | 1.63% | 24.90% |
| Normalized Diluted EPS | -5.88% | -8.93% | -5.78% | 1.73% | 24.94% |
| Average Basic Shares Outstanding | 36.16% | 23.52% | 12.98% | 6.21% | 7.11% |
| Average Diluted Shares Outstanding | 36.16% | 23.52% | 12.98% | 6.21% | 7.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |